feed,title,long_url,short_url
Benzinga,Three In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young Boys,https://benzinga.com/analyst-ratings/analyst-color/23/08/34109907/three-in-a-row-fibrogens-investigational-drug-flunks-in-another-study-for-rare-dise,https://da.gd/JsrZLL
Benzinga,Why Is Outlook Therapeutics Stock Nosediving Today?,https://benzinga.com/general/biotech/23/08/34110438/why-is-outlook-therapeutics-stock-nosediving-today,https://da.gd/iwz4uQ
